E-ISSN 2148-5607
RELATED ARTICLES
Editorial
Apoptosis in selected liver diseases
(Turk J Gastroenterol 2009; 20: 171-179)
DOI: 10.4318/tjg.2009.0003
The prevalence of hepatocellular carcinoma in patients with liver cirrhosis in Southeastern Turkey
(Turk J Gastroenterol 1998; 9: 217-220)
Lamivudine resistance in untreated chronic hepatitis B patients in Turkey
(Turk J Gastroenterol 2008; 19: 99-103)
Prevalence and clinical significance of SEN-H virus in chronic hepatitis B, C and delta infections in Turkey
(Turk J Gastroenterol 2008; 19: 104-108)
The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: An analysis of clinical studies
(Turk J Gastroenterol 2006; 17: 25-34)
Daily consensus interferon (CIFN) monotherapy in non-responders or relapsers to a previous interferon regime: One year follow-up after 48 weeks of treatment
(Turk J Gastroenterol 2006; 17: 35-39)
The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients
(Turk J Gastroenterol 2006; 17: 94-98)
The value of ultrasonography in the diagnosis of early cirrhosis*
(Turk J Gastroenterol 1999; 10: 7-10)
An asymptomatic huge hepatocellular carcinoma with intra-atrial tumor thrombus in a patient with chronic hepatitis B viral infection
(Turk J Gastroenterol 2006; 17: 203-205)
Assessment of bone metabolism and mineral density in chronic viral hepatitis
(Turk J Gastroenterol 2006; 17: 260-266)
Hepatitis B and C virus in West-Central Turkey: Seroprevalence in healthy individuals admitted to a university hospital for routine health checks
(Turk J Gastroenterol 2006; 17: 267-272)
P21 expression and its relation to disease activity and hepatocyte proliferation in chronic hepatitis B virus infection
(Turk J Gastroenterol 2005; 16: 12-16)
Determination of hepatitis B genotypes in patients with chronic hepatitis B virus infection in Turkey
(Turk J Gastroenterol 2005; 16: 183-187)
Immunomodulatory effects of HBsAg vaccine and levamisole in chronic hepatitis B and hepatitis B carrier children
(Turk J Gastroenterol 2005; 16: 188-193)
E-cadherin expression in hepatitis B virus related hepatocelluler carcinoma: Comparison of normal, chronic hepatitis and cirrhotic liver
(Turk J Gastroenterol 1999; 10: 92-94)
Seroepidemiology of delta hepatitis in Turkey
(Turk J Gastroenterol 1999; 10: 316-327)
Hepatitis B seroprevalance and risk factors in urban areas of Malatya
(Turk J Gastroenterol 2002; 13: 1-5)
The effect of recombinant hepatitis B vaccine therapy in chronic hepatitis B infection
(Turk J Gastroenterol 2002; 13: 6-10)
Alanine aminotransferase deficiency in a hepatitis B surface antigen positive patient presenting with acute hepatitis
(Turk J Gastroenterol 2002; 13: 60-62)
The value of fine needle aspiration biopsy in the diagnosis of metastatic liver tumours
(Turk J Gastroenterol 2002; 13: 78-82)
Diagnostic value of color doppler ultrasonography in hepatocellular carcinoma
(Turk J Gastroenterol 1996; 7: 298-302)
Clinicopathologic features and risk factors for hepatocellular carcinoma: Results from a single center in southern Turkey
(Turk J Gastroenterol 2003; 14: 85-90)
Two cases with hepatocellular carcinoma and spleen metastasis
(Turk J Gastroenterol 2003; 14: 138-140)
Determination of serum hepatitis B virus DNA in chronic HBsAg carriers: Clinical significance and correlation with serological markers
(Turk J Gastroenterol 2003; 14: 157-163)
The use of tissue polypeptide specific antigen as a marker in liver diseases
(Turk J Gastroenterol 2003; 14: 177-180)
Clear cell carcinoma of the liver: A case report
(Turk J Gastroenterol 2003; 14: 211-214)
A comparative immunohistochemical study of HBsAg, HBcAg and CD57 in chronic hepatitis B pediatric patients with and without malignant disorders
(Turk J Gastroenterol 2003; 14: 234-238)
An analysis of our with hepatocellular carcinoma
(Turk J Gastroenterol 1997; 8: 36-40)
histological outcome after interferon therapy in chronic viral hepatitis
(Turk J Gastroenterol 1997; 8: 291-294)
Effect of interferon treatment on glucose metabolism in children with chronic hepatitis B infection
(Turk J Gastroenterol 2004; 15: 4-10)
Hepatitis B carriage and Brucella seroprevalence in urban and rural areas of Bolu province of Turkey: A prospective epidemiologic study
(Turk J Gastroenterol 2004; 15: 11-13)
A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels
(Turk J Gastroenterol 2004; 15: 14-20)
Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha
(Turk J Gastroenterol 2004; 15: 213-218)
Predictive value of proliferating cell nuclear antigen index in response to interferon treatment in patients with chronic viral hepatitis B and C
(Turk J Gastroenterol 2001; 12: 89-94)
Effects of Giardia lamblia infestation on the clinical sourse of cronic hepatitis B
(Turk J Gastroenterol 1998; 9: 24-27)
Acral erythema induced bu interferon alpha in a child
(Turk J Gastroenterol 1998; 9: 70-72)
Effect of anti-HCV positifity on response to hepatitis B virus vaccine in haemodialysis patients
(Turk J Gastroenterol 1998; 9: 105-107)
Diagnostic value of serum copper, zinc and plasma fibrinogen in cirrhotic patients with and without hepatocellular carcinoma
(Turk J Gastroenterol 1998; 9: 108-112)
Etiologies of chronic hepatitis
(Turk J Gastroenterol 1998; 9: 113-115)
Evaluation of the outcome of interferon therapy in chronic hepatitis B infection
(Turk J Gastroenterol 1999; 10: -)
Autoantibodies in chronic viral hepatitis and autoimmune hepatitis
(Turk J Gastroenterol 1997; 8: 381-384)
Response to hepatitis B vaccine in patients with non-hepatitis B chronic liver disease
(Turk J Gastroenterol 1997; 8: 148-151)
Seroprevalence of hepatitis B and C viruses in the province of Tokat in the Black Sea region of Turkey: A population-based study
(Turk J Gastroenterol 2009; 20: 27-30)
Transmission routes of chronic hepatitis C and their relation to HCV genotypes
(Turk J Gastroenterol 2010; 21: 396-400)
DOI: 10.4318/tjg.2010.0126
Determination of intracellular Th1/Th2 type cytokines in lymphocytes of chronic hepatitis B patients treated with interferon-alpha
(Turk J Gastroenterol 2010; 21: 401-410)
DOI: 10.4318/tjg.2010.0127
Relationship between serum levels of interleukin-10, interleukin-2 and soluble intercellular adhesion molecule-I and liver injury in chronic hepatitis B virus infection
(Turk J Gastroenterol 1999; 10: 243-248)
HCV genotypes in HCV related chronic hepatitis in Southeast Anatolia
(Turk J Gastroenterol 1999; 10: 249-252)
Review
Emerging therapeutics and relevant targets for chronic Hepatitis B
(Turk J Gastroenterol 2016; 27: 210-215)
DOI: 10.5152/tjg.2016.15521
Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report
(Turk J Gastroenterol 2018; 29: 259-269)
DOI: 10.5152/tjg.2018.18263
Case Report
A case of gynecomastia due to entecavir
(Turk J Gastroenterol 2010; 21: 313-316)
DOI: 10.4318/tjg.2010.0108
A case of entecavir-associated bullous fixed drug eruption and a review of literature
(Turk J Gastroenterol 2019; 30: 299-302)
DOI: 10.5152/tjg.2018.17887
A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B
(Turk J Gastroenterol 2014; 25: 206-209)
DOI: 10.5152/tjg.2014.3605
Synchronous occurrence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in both lobes of the liver
(Turk J Gastroenterol 2014; 25: 209-211)
DOI: 10.5152/tjg.2014.6188
Hepatocellular carcinoma presenting as a huge intra-abdominal mass: A case report
(Turk J Gastroenterol 2014; 25: 330-332)
DOI: 10.5152/tjg.2014.3255
Original Article
Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection
(Turk J Gastroenterol 2014; 25: 142-146)
DOI: 10.5152/tjg.2014.5711
Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis
(Turk J Gastroenterol 2014; 25: 147-152)
DOI: 10.5152/tjg.2014.4888
18F-FDG PET CT as a prognostic factor in hepatocellular carcinoma
(Turk J Gastroenterol 2015; 26: 344-350)
DOI: 10.5152/tjg.2015.0152
Gallstones in liver transplant recipients: A single-center study in China
(Turk J Gastroenterol 2015; 26: 429-434)
DOI: 10.5152/tjg.2014.6344
AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2011; 22: 279-285)
DOI: 10.4318/tjg.2011.0213
AST-platelet ratio index in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis B
(Turk J Gastroenterol 2012; 23: 353-358)
DOI: 10.4318/tjg.2012.0348
Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B
(Turk J Gastroenterol 2012; 23: 247-252)
DOI: 10.4318/tjg.2012.0380
Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients
(Turk J Gastroenterol 2012; 23: 538-545)
DOI: 10.4318/tjg.2012.0358
Alpha-1 antitrypsin deficiency in patients with chronic hepatitis
(Turk J Gastroenterol 2012; 23: 569-573)
DOI: 10.4318/tjg.2012.0379
Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience
(Turk J Gastroenterol 2013; 24: 141-147)
DOI: 10.4318/tjg.2013.0709
Prevelance of hepatitis D co-enfection in children with hepatitis B infection: Cross-sectional analyses from Western Turkey
(Turk J Gastroenterol 2013; 24: 345-348)
DOI: 10.4318/tjg.2013.0681
Characteristics of patients dying from acute viral hepatitis in Serbia
(Turk J Gastroenterol 2011; 22: 152-157)
DOI: 10.4318/tjg.2011.0184
MR imaging in diffuse-type hepatocellular carcinoma with synchronous portal vein thrombi
(Turk J Gastroenterol 2011; 22: 158-164)
DOI: 10.4318/tjg.2011.0185
Responsiveness of children with celiac disease to different hepatitis B vaccination protocols
(Turk J Gastroenterol 2011; 22: 27-31)
DOI: 10.4318/tjg.2011.0152
Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir
(Turk J Gastroenterol 2016; 27: 42-46)
DOI: 10.5152/tjg.2015.150348
The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B
(Turk J Gastroenterol 2015; 26: 36-41)
DOI: 10.5152/tjg.2015.4636
Evaluation of local tumor residue after percutaneous radiofrequency ablation therapy for hepatocellular carcinoma
(Turk J Gastroenterol 2017; 28: 197-201)
DOI: 10.5152/tjg.2017.16641
Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
(Turk J Gastroenterol 2016; 27: 55-61)
DOI: 10.5152/tjg.2015.150280
Routinely evaluated clinical assays and laboratory tests [real test] and fibrosis stages of chronic hepatitis B and C
(Turk J Gastroenterol 2014; 25: 539-545)
DOI: 10.5152/tjg.2014.6170
The predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2016; 27: 156-164)
DOI: 10.5152/tjg.2015.150449
The association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C: An observational, multicenter study in Turkey
(Turk J Gastroenterol 2014; 25: 546-552)
DOI: 10.5152/tjg.2014.7829
Public awareness of hepatitis B infection in Turkey as a model of universal effectiveness in health care policy
(Turk J Gastroenterol 2014; 25: 304-308)
DOI: 10.5152/tjg.2014.6718
Combination of DKK1 and AFP improves diagnostic accuracy of hepatocellular carcinoma compared with either marker alone
(Turk J Gastroenterol 2016; 27: 375-381)
DOI: 10.5152/tjg.2016.15523
Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B
(Turk J Gastroenterol 2016; 27: 279-283)
DOI: 10.5152/tjg.2016.16085
Quick Look to Guidelines
Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines
(Turk J Gastroenterol 2017; 28: 518-521)
DOI: 10.5152/tjg.2017.171017
Liver - Original Article
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey
(Turk J Gastroenterol 2019; 30: 331-335)
DOI: 10.5152/tjg.2018.18269
Percutaneous microwave ablation for HCV-related hepatocellular carcinoma: Efficacy, safety, and survival
(Turk J Gastroenterol 2019; 30: 445-453)
DOI: 10.5152/tjg.2019.17191
Seroprevalence of hepatitis B, hepatitis C, and HIV in pregnant women from Eastern Turkey
(Turk J Gastroenterol 2019; 30: 260-265)
DOI: 10.5152/tjg.2018.17634
Assessing the characteristics and feasibility of preventing early mortality in patients with hepatocellular carcinoma
(Turk J Gastroenterol 2019; 30: 541-548)
DOI: 10.5152/tjg.2019.18654
Contrast-enhanced ultrasound-guided radiofrequency ablation in inconspicuous hepatocellular carcinoma on B-mode ultrasound
(Turk J Gastroenterol 2017; 28: 446-452)
DOI: 10.5152/tjg.2017.17104
Regular hospital visits improve the prognosis of hepatocellular carcinoma after initial diagnosis: A single regional community hospital study
(Turk J Gastroenterol 2017; 28: 353-360)
DOI: 10.5152/tjg.2017.17163
Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity
(Turk J Gastroenterol 2018; 29: 561-565)
DOI: 10.5152/tjg.2018.18032
Assessing the outcome of patients with liver cirrhosis during hospital stay: A comparison of lymphocyte/monocyte ratio with MELD and Child-Pugh scores
(Turk J Gastroenterol 2018; 29: 308-315)
DOI: 10.5152/tjg.2018.17631
Does steatosis affect the performance of diffusion-weighted MRI values for fibrosis evaluation in patients with chronic hepatitis C genotype 4?
(Turk J Gastroenterol 2017; 28: 283-288)
DOI: 10.5152/tjg.2017.16640
Lamivudine’s efficacy and safety in preventing mother-to-child transmission of hepatitis B: A meta-analysis
(Turk J Gastroenterol 2019; 30: 66-74)
DOI: 10.5152/tjg.2018.18148
Role of nucleoside/nucleotide analogues and low-dose hepatitis B immune globulin in prophylaxis of hepatitis B recurrence among cadaveric liver transplant recipients
(Turk J Gastroenterol 2018; 29: 61-66)
DOI: 10.5152/tjg.2018.17595
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study
(Turk J Gastroenterol 2018; 29: 464-472)
DOI: 10.5152/tjg.2018.16597
Percutaneous microwave ablation for HCV-related hepatocellular carcinoma: Efficacy, safety, and survival
(Turk J Gastroenterol ; : -)
DOI: 10.5152/tjg.2019.17191
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study
(Turk J Gastroenterol ; : -)
DOI: 10.5152/tjg.2018.16597
Basic & Translational - Original Article
Claudin-9 enhances the metastatic potential of hepatocytes via Tyk2/Stat3 signaling
(Turk J Gastroenterol ; : -)
DOI: 10.5152/tjg.2019.18513
An in vivo RNAi mini-screen in Drosophila cancer models reveals novel potential Wnt targets in liver cancer
(Turk J Gastroenterol 2019; 30: 198-207)
DOI: 10.5152/tjg.2018.18241
Oral Presentation
Effects of small molecule inhibitors on liver cancer stem cells in comparison with Sorafenib
(Turk J Gastroenterol 2019; 30: 7-7)
DOI: 10.5152/tjg.2019.05
Poster
Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience
(Turk J Gastroenterol 2019; 30: 10-15)
DOI: 10.5152/tjg.2019.07
Nonsirotic chronic hepatitis B presenting with hepatocellular carcinoma: a case report
(Turk J Gastroenterol 2019; 30: 16-17)
DOI: 10.5152/tjg.2019.08
Retrospective Investigation of De novo hepatitis B infection in recipients after liver transplantation by anti-HBc positive donors
(Turk J Gastroenterol 2019; 30: 20-20)
DOI: 10.5152/tjg.2019.10
Evaluation of rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive treatment
(Turk J Gastroenterol 2019; 30: 25-25)
DOI: 10.5152/tjg.2019.14
From cirrhosis to hepatocellular carcinoma: An investigation into hepatitis C viral oncogenesis using meta-analysis
(Turk J Gastroenterol 2019; 30: 26-28)
DOI: 10.5152/tjg.2019.15
Successfully treatment of chronic hepatitis C with direct-acting antiviral agents: a single center experience
(Turk J Gastroenterol 2019; 30: 34-34)
DOI: 10.5152/tjg.2019.20
Efficacy of entecavir treatment for up to 5 years in patients with HBV-related compensated cirrhosis in Turkey; real life data
(Turk J Gastroenterol 2019; 30: 36-36)
DOI: 10.5152/tjg.2019.22
Hepatitis b reactivation rate in patients using anti tnf theraphy: Evaluation of patients not received anti viral prophylaxis
(Turk J Gastroenterol 2019; 30: 38-38)
DOI: 10.5152/tjg.2019.24
A real-life evaluation of the effect of direct-acting antivirals in hemodialysis patients with chronic hepatitis C
(Turk J Gastroenterol 2019; 30: 39-40)
DOI: 10.5152/tjg.2019.25
Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medication with patients with chronic hepatitis C virus infection
(Turk J Gastroenterol 2019; 30: 43-45)
DOI: 10.5152/tjg.2019.28
Evaluation of 24-year followig results of patients with inactive hepatitis B
(Turk J Gastroenterol 2019; 30: 55-55)
DOI: 10.5152/tjg.2019.35
Diagnostic value of computerized tomography ın differential diagnosis of liver nodules
(Turk J Gastroenterol 2019; 30: 64-64)
DOI: 10.5152/tjg.2019.41
Liver biopsy may not be the optimal option for assessing treatment efficacy in chronic hepatitis delta (CHD) infection
(Turk J Gastroenterol 2019; 30: 67-67)
DOI: 10.5152/tjg.2019.44
A case with chronic HBV infection who was non-responder to nucleos(t)ide analogues was treated with Pegylated interferon
(Turk J Gastroenterol 2019; 30: 70-72)
DOI: 10.5152/tjg.2019.47
Prospective and Randomized Comparison of Tenofovir and Entecavir in Hepatitis B Reactivation Prophylaxis in Patients Receiving Immunosuppressive Therapy
(Turk J Gastroenterol 2019; 30: 73-73)
DOI: 10.5152/tjg.2019.48
Clinical and laboratory features of children with chronic hepatitis B infection: A single center results
(Turk J Gastroenterol 2019; 30: 74-74)
DOI: 10.5152/tjg.2019.49
Acute liver ınjury in a patient with secondary syphilis and acute viral hepatitis B coinfection
(Turk J Gastroenterol 2019; 30: 75-75)
DOI: 10.5152/tjg.2019.50
Clinical outcomes after cessation of potent antiviral treatment in chronic hepatitis B patients
(Turk J Gastroenterol 2019; 30: 81-82)
DOI: 10.5152/tjg.2019.54
Diagnosis ways of chronic HBV cases
(Turk J Gastroenterol 2019; 30: 86-86)
DOI: 10.5152/tjg.2019.57
Comparison of antivirals in prophylaxis of HBV reactivation in patients receiving immunsuppressive therapy
(Turk J Gastroenterol 2019; 30: 92-92)
DOI: 10.5152/tjg.2019.61
Poster Presentation
Evaluation of diagnostic performance simple non-invasıve fibrosis markers in patients with chronic hepatitis B
(Turk J Gastroenterol 2019; 30: 100-100)
DOI: 10.5152/tjg.2019.65
The evaluation of liver biopsy specimens of chronic hepatitis B patients using early tissue markers for Hepatocellular Carcinoma: Before and after the development of Hepatocellular Carcinoma
(Turk J Gastroenterol 2019; 30: 102-102)
DOI: 10.5152/tjg.2019.67
Key Words
Authors
All
Reviewer's Corner
Author’s Corner
Survey
AVES | Copyright © 2019 Turkish Society of Gastroenterology | Latest Update: 30.05.2019